Journal Article

The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant Staphylococcus aureus

Zou, Guijin, Kim, Soo Min, Pan, Wen, Faizi, Hammad A., Fricke, Nico, Gao, Huajian, Mylonakis, Eleftherios, Escorba, Iliana, Vlahovska, Petia M., Li, Silei, Kim, Wooseong, Ausubel, Frederick M., Lee, Kiho, Khader, Rajamohammed

2020

Overview

Membrane-damaging antimicrobial agents have great potential to treat multidrug-resistant or multidrug-tolerant bacteria against which conventional antibiotics are not effective. However, their therapeutic applications are often hampered due to their low selectivity to bacterial over mammalian membranes or their potential for cross-resistance to a broad spectrum of cationic membrane-active antimicrobial agents. We discovered that the diarylurea derivative compound PQ401 has antimicrobial potency against multidrug-resistant and multidrug-tolerant Staphylococcus aureus . PQ401 selectively disrupts bacterial membrane lipid bilayers in comparison to mammalian membranes. Unlike cationic membrane-active antimicrobials, the neutral form of PQ401 rather than its cationic form exhibits maximum membrane activity. Overall, our results demonstrate that PQ401 could be a promising lead compound that overcomes the current limitations of membrane selectivity and cross-resistance. Also, this work provides deeper insight into the design and development of new noncharged membrane-targeting therapeutics to combat hard-to-cure bacterial infections. Resistance or tolerance to traditional antibiotics is a challenging issue in antimicrobial chemotherapy. Moreover, traditional bactericidal antibiotics kill only actively growing bacterial cells, whereas nongrowing metabolically inactive cells are tolerant to and therefore “persist” in the presence of legacy antibiotics. Here, we report that the diarylurea derivative PQ401, previously characterized as an inhibitor of the insulin-like growth factor I receptor, kills both antibiotic-resistant and nongrowing antibiotic-tolerant methicillin-resistant Staphylococcus aureus (MRSA) by lipid bilayer disruption. PQ401 showed several beneficial properties as an antimicrobial lead compound, including rapid killing kinetics, low probability for resistance development, high selectivity to bacterial membranes compared to mammalian membranes, and synergism with gentamicin. In contrast to well-studied membrane-disrupting cationic antimicrobial low-molecular-weight compounds and peptides, molecular dynamic simulations supported by efficacy data demonstrate that the neutral form of PQ401 penetrates and subsequently embeds into bacterial lipid bilayers more effectively than the cationic form. Lastly, PQ401 showed efficacy in both the Caenorhabditis elegans and Galleria mellonella models of MRSA infection. These data suggest that PQ401 may be a lead candidate for repurposing as a membrane-active antimicrobial and has potential for further development as a human antibacterial therapeutic for difficult-to-treat infections caused by both drug-resistant and -tolerant S. aureus . IMPORTANCE Membrane-damaging antimicrobial agents have great potential to treat multidrug-resistant or multidrug-tolerant bacteria against which conventional antibiotics are not effective. However, their therapeutic applications are often hampered due to their low selectivity to bacterial over mammalian membranes or their potential for cross-resistance to a broad spectrum of cationic membrane-active antimicrobial agents. We discovered that the diarylurea derivative compound PQ401 has antimicrobial potency against multidrug-resistant and multidrug-tolerant Staphylococcus aureus . PQ401 selectively disrupts bacterial membrane lipid bilayers in comparison to mammalian membranes. Unlike cationic membrane-active antimicrobials, the neutral form of PQ401 rather than its cationic form exhibits maximum membrane activity. Overall, our results demonstrate that PQ401 could be a promising lead compound that overcomes the current limitations of membrane selectivity and cross-resistance. Also, this work provides deeper insight into the design and development of new noncharged membrane-targeting therapeutics to combat hard-to-cure bacterial infections.

• Publisher: American Society for Microbiology
• Subject: Aminoquinolines - pharmacology / Animals / Anti-Bacterial Agents - pharmacology / antibiotic / Antibiotic resistance / antibiotic tolerance / Antibiotics / Antimicrobial agents / antimicrobial resistance / Bacteria / Caenorhabditis elegans - microbiology / Chemotherapy / Cross-resistance / Drug resistance / Drug Synergism / Gentamicin / Gentamicins - pharmacology / Gram-positive bacteria / Hemolysis - drug effects / Host-Microbe Biology / Humans / Insulin-like growth factor I / Insulin-like growth factors / Larva - microbiology / Lipid bilayers / membrane-active antimicrobials / Membranes / Methicillin / Methicillin-Resistant Staphylococcus aureus - drug effects / Microbial Sensitivity Tests / Molecular Dynamics Simulation / Moths - microbiology / MRSA / Multidrug resistance / Nosocomial infections / Pathogens / persisters / Phenylurea Compounds - pharmacology / Staphylococcal Infections - microbiology / Staphylococcus aureus / Staphylococcus aureus - drug effects / Staphylococcus infections / Therapeutic applications